Related Experiment Video
Updated: Dec 24, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Chapter 22. Non-HIV antiviral agents
Nicholas A Meanwell1, Michael H Serrano-Wu1, Lawrence B Snyder1
1Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway, Wallingford, CT 06492, USA.
Abstract:
This chapter focuses on non-HIV antiviral agents. The development of antiviral agents to treat non-HIV infections is largely focused on therapies for the treatment of chronic hepatitis infections B and C. Nucleoside analog continue to be the mainstay of Hepatitis B Virus (HBV) therapeutics. The first small molecule inhibitor of Hepatitis C Virus (HCV), the NS3 protease inhibitor BILN-2061, entered phase 2 clinical trials, producing a striking reduction in viral load in treated individuals. The development of the HCV replicon system and its application to screening for antiviral agents provided tangible benefit with the disclosure of mechanistically and structurally diverse HCV inhibitors. Adefovir dipivoxil has been approved in the United States and the European Union for the treatment of HBV, providing a second small molecule antiviral to add to lamivudine (3TC) and the injectable protein IFNα as the only approved agents for treating HBV infection. The chapter also provides details of the inhibitors of hepatitis B and C virus, the inhibitors of simplex virus and human cytomegalovirus, the inhibitors of respiratory viruses and the inhibitors of West Nile virus and Papilloma virus.
Related Concept Videos
Retrovirus Life Cycles
Subviral Agents
Retroviruses
Size and Structure of Viral Genomes
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Viruses with RNA Genomes

